Unicycive Therapeutics Inc (UNCY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.16-2.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · UNCY
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 0.7 | 1.0 | — | — |
| Total Revenues | — | — | — | 0.7 | 1.0 | — | — |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | — | — | — | — | 0.4 | 0.2 | 0.1 |
| R&D Expenses | 9.6 | 9.1 | 20.0 | 12.9 | 12.4 | 6.1 | 1.0 |
| Operating Income | (33.1) | (29.5) | (32.1) | (20.8) | (18.1) | (9.0) | (2.0) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 0.1 | 0.1 | 0.1 | 0.0 | 0.6 | 0.2 |
| Interest & Investment Income | 1.5 | 1.0 | 1.3 | 0.6 | — | — | — |
| Net Interest Expenses | — | — | — | (0.5) | — | — | — |
| Other Non-Operating Income / Expenses | (2.1) | 3.0 | (4.6) | (9.8) | (0.0) | (1.0) | (0.2) |
| Net Income | |||||||
| Net Income | (35.2) | (26.6) | (36.7) | (30.5) | (18.1) | (10.0) | (2.3) |
| Per Share | |||||||
| Basic EPS | (1.31) | (1.67) | (0.56) | (1.28) | (1.20) | (0.86) | (0.27) |
| Diluted EPS | (1.31) | (1.67) | (0.56) | (1.28) | (1.20) | (0.86) | — |
| Basic Weighted Avg Shares | 26.9 | 15.9 | 67.0 | 24.5 | 15.1 | 11.7 | 8.5 |
| Diluted Weighted Avg Shares | 26.9 | 15.9 | 67.0 | 24.5 | 15.1 | 11.7 | — |
| Supplemental | |||||||
| EBITDA | — | — | — | — | (17.6) | (8.5) | — |
| EBIT | (33.1) | (29.5) | (32.1) | (20.8) | (18.1) | (9.0) | (2.0) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.